Podcast appearances and mentions of ross camidge

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. In this episode, Dr Camidge sat down with Alexandra Rink, PhD, a medical physicist at Princess Margaret Cancer Centre; a clinician scientist at the Princess Margaret Research Institute; and an associate professor in the Departments of Radiation Oncology and Medical Biophysics at the University of Toronto in Canada. Drs Camidge and Rink discussed how Dr Rink's early career interest in forensics led her down the path toward becoming a medical physicist, how physics factor into radiation therapy delivery, and the importance of multidisciplinary collaboration to deliver optimal patient care.

Drs Camidge and Nechtman discuss Nechtman's experience supporting and caring for his wife Laura during her lung cancer diagnosis and treatment; the emotional and practical challenges they faced as a family during her battle with cancer; and Nechtman's commitment to continuing Laura's patient advocacy work to advance lung cancer research. 

Drs Camidge and Oxnard discussed Dr Oxnard's work with novel EGFR inhibitors that aims to overcome treatment resistance; how advancements in precision medicine have increased the importance of early cancer detection; and how he balances clinical practice with his industry role, advocating for efficient, patient-centered care

Drs Camidge and Studts discussed Dr Studts' career in behavioral science, particularly in lung cancer prevention and control. Dr Studts shared his journey from having a high school interest in psychology to assuming his current role at the University of Colorado.

Drs Camidge and Eisen discussed Dr Eisen's dual career in academia and industry. Growing up in London, he pursued medicine, excelling in cell pathology at University College London, and later specialized in oncology at Cambridge. He joined Roche in 2020. Dr Eisen emphasized the importance of aligning academic and clinical strengths, advocating for industry experience to enhance drug development. He aims to foster interfaces between academia and industry, ensuring sustainable health research and training the next generation of drug developers.

Drs Camidge and Eisen discussed Dr Eisen's dual career in academia and industry. Growing up in London, he pursued medicine, excelling in cell pathology at University College London, and later specialized in oncology at Cambridge. He joined Roche in 2020. Dr Eisen emphasized the importance of aligning academic and clinical strengths, advocating for industry experience to enhance drug development. He aims to foster interfaces between academia and industry, ensuring sustainable health research and training the next generation of drug developers.

In this episode, Dr Camidge is rejoined by Rahul Gosain, MD, MBA, the medical director of Wilmot Cancer Institute at Webster and director of Wilmot Cancer Institute Regional Infusion services, as well as an assistant professor of clinical medicine in the Department of Medicine, Hematology/Oncology at the University of Rochester in New York. Dr Gosain is also co-host of the podcast Oncology Brothers.

Drs Camidge and Boire discuss Dr Boire's journey to becoming a physician-scientist, moments in her career that shaped her fascination with neurology, and how studying human biology at the cellular level can ultimately help improve the lives of patients with cancer.

Drs Camidge and Redman discuss Dr Redman's role as a biostatistician, outlining her work in designing clinical trials, navigating collaborations with multidisciplinary care teams, and the challenges of coordinating efforts across a nationwide network of clinical researchers.

In this episode, Dr Camidge sits down with Michael Smylie, MBBS, FRCPC, a professor in the Department of Oncology in the Faculty of Medicine and Dentistry at the University of Alberta and a medical oncologist at the Cross Cancer Institute in Edmonton, Canada.  Drs Camidge and Smylie discussed Dr Smylie's experience treating patients who live in the Northwest Territories of Canada, including the challenges he encounters when providing oncology care to such a vast geographic area, unique considerations when treating a predominantly indigenous community, and how his own colon cancer diagnosis influenced his relationship with patients.

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. In this episode, Dr Camidge sits down with Rahul Gosain, MD, MBA, the medical director of Wilmot Cancer Institute at Webster and director of Wilmot Cancer Institute Regional Infusion services, as well as an assistant professor of clinical medicine in the Department of Medicine, Hematology/Oncology at the University of Rochester in New York. He is also co-host of the podcast Oncology Brothers. Drs Camidge and Gosain discuss how Dr Gosain's journey through medical school led him to his role as a community oncologist, the challenges he encountered during his early career that inspired him to fill a need for concise yet comprehensive educational resources, and how he harnessed social media and leveraged professional connections to create a podcast highlighting practice updates for up-and-coming oncology professionals.

In this episode, Dr Camidge sits down with Duncan McLaren, MBBS, BSc, FRCR, FRCP, a consultant clinical oncologist at Spire Edinburgh Hospitals Murrayfield and Shawfair Park, as well as a professor at the Edinburgh Cancer Research Centre at The University of Edinburgh in Scotland. Drs Camidge and McLaren discuss Dr McLaren's unconventional journey to medical school, his experience as a clinical oncologist with expertise across oncology disciplines, and how his clinical research focus works to change the course of radiation therapy for genitourinary cancers.

Description: As the incidence of lung cancer in those under age 35 increases, oncologists are finding that pregnancy is a central issue for many young women who are coping with lung cancer. In this episode of Lung Cancer Considered, host Dr. Narjust Florez and guests discuss some of the critical issues facing women with lung cancer who are pregnant, or attempting to start a family. Guest: Dr. Ross Camidge is a Thoracic Medical Oncologist and the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado. Guest: Dr. Martina Imbimbo is a Thoracic Medical Oncologist at the IOSI Oncology Institute of Southern Switzerland where she specializes in immunooncology and targeted therapy.

In this episode, Dr Camidge sits down with Douglas Ney, MD, a professor of neurology and neurosurgery, program director of the Neurology Residency Program, and vice-chair of Education in the Department of Neurology at the University of Colorado Cancer Center in Aurora.  Drs Camidge and Ney discuss Dr Ney's journey to becoming a neurologic oncologist, how the management of primary brain tumors differs from that of brain metastases in his practice, and his experience as a physician with Tourette syndrome.

In this episode, Dr Camidge sits down with Jeanne Fourie Zirkelbach, PhD, a clinical pharmacologist in the Office of Clinical Pharmacology in the Center for Drug Evaluation and Research at the FDA.  Drs Camidge and Zirkelbach discuss how Zirkelbach got her start in the pharmacokinetics field; her involvement with Project Optimus, an initiative by the FDA's Oncology Center of Excellence that works to reform dose-optimization and -selection paradigms in oncology drug development; and how her research with patient-reported outcomes emphasizes the importance of keeping patient needs, preferences, and experiences at the forefront of drug development to minimize the effects of cancer treatment on quality of life.

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. In this episode, Dr Camidge sits down with Kadrin Wilfong, MD, to discuss her career in the field of continuing medical education (CME). Dr Wilfong is the vice president of Medical Education at PeerView Institute for Medical Education in New York, New York.  Drs Camidge and Wilfong talk through Wilfong's multifaceted journey to medical school, how her passion for the medical field propelled her career in oncology-focused education, the ins and outs of developing CME, and how educational events and resources can make a difference in the care of patients with cancer. 

CME credits: 0.25 Valid until: 25-10-2024 Claim your CME credit at https://reachmd.com/programs/cme/met-inhibition-in-metastatic-nsclc-in-the-spotlight/14786/ Drs. Paul Paik, Keith Kerr, and Ross Camidge take us through testing considerations for MET exon 14 skipping mutations and optimal treatment approaches once a mutation is detected. They also discuss the emerging data and how to apply what we're learning to everyday clinical practice.=

World-renowned oncologist D. Ross Camidge, MD, PhD, sits down with guests to discuss the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. 

World-renowned oncologist D. Ross Camidge, MD, PhD, sits down with guests to discuss the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. 

World-renowned oncologist D. Ross Camidge, MD, PhD, sits down with guests to discuss the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. 

D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC

D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC

D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC

D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC

D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC

D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC

World-renowned oncologist D. Ross Camidge, MD, PhD, sits down with guests to discuss the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. 

World-renowned oncologist D. Ross Camidge, MD, PhD, sits down with guests to discuss the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. 

World-renowned oncologist D. Ross Camidge, MD, PhD, sits down with guests to discuss the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. 

World-renowned oncologist D. Ross Camidge, MD, PhD, sits down with guests to discuss the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. 

Featuring a discussion on the management of ALK-positive lung cancer with Dr Ross Camidge, Dr Justin Gainor, Prof Solange Peters and Prof Ben Solomon, moderated by Dr Neil Love.

World-renowned oncologist D. Ross Camidge, MD, PhD, sits down with guests to discuss the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. 

On today's episode, meet Dr. Sami Diab. Dr. Diab is a Medical Oncologist and Medical Director of Lone Tree Oncology, part of the University of Colorado Health System. He attended medical school at Damascus University, in Damascus, Syria followed by residency at Wayne State University, in Detroit, MI. He did his fellowship in Medical Oncology at the University of Texas, MD Anderson Hospital and Tumor Institute, in Houston and a fellowship in Integrative Medicine, at the University of Arizona. Dr. Ross Camidge calls him "arguably one of the most informed general oncologists I know."

On today's episode, meet Dr. Ross Camidge. Dr. Camidge has been the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado since 2007. He earned his medical degree from University of Oxford, and his PhD from University of Cambridge after receiving his undergraduate degree at Oxford University. Beyond the medicine, Dr. Camidge and all members of his team also believe they should look after every patient, and their friends and family, as they would want their own friends and family to be looked after.

World-renowned oncologist D. Ross Camidge, MD, PhD, sits down with guests to discuss the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. 

This episode of Lung Cancer Considered covers a subset of patients with non-small cell lung cancer with lung cancer -- MET exon 14 skipping mutations. MET exon 14 skipping mutations occur in approximately 3 to 4% of patients with NSCLC, typically in the absence of other driver mutations. Host Dr. Narjust Florez will discuss the unique clinical issues surrounding MET exon with Dr. Ross Camidge, Director of the Clinical and Research Thoracic Program at the University of Colorado and Dr. Noemi Reguart, Clinical Professor at the University of Barcelona.

In this second of two episodes, Dr. Iyad Alnahhas interviews Drs. Ross Camidge, Michael Davis, Nancy Lin and Ayal Aizer about the recent editorial review entitled: "Brain Metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions", published online in Neuro-Oncology in June 2022.  Full Report

Featuring perspectives from Dr Ross Camidge, including the following topics: Introduction: First-line systemic treatment; brain metastases (0:00) Case: A woman in her early 60s with squamous NSCLC metastatic to tbe brain and an ALK rearrangement; PD-L1 TPS 70% — Spencer Henick Bachow, MD (20:30) Case: A man in his early 70s with localized NSCLC with an ALK rearrangement and significant comorbidities — Sunil Gandhi, MD (24:44) Case: A woman and heart transplant recipient in her mid 70s with metastatic NSCLC with a KRAS G12C mutation; PD-L1 TPS 20% — Mamta Choksi, MD (30:26) Case: A woman in her late 70s with metastatic NSCLC and a MET exon 14 skipping mutation — Jennifer L Dallas, MD (36:01) Case: A woman in her late 60s with metastatic NSCLC and a HER2 exon 19 mutation pathogenic variant; PD-L1 TPS 15% — Rajni Sinha, MD, MRCP (41:43) Case: A man in his early 30s with metastatic NSCLC and an NTRK fusion; PD-L1 TPS 10% — Daniel R Carrizosa, MD, MS (46:09) Treatment for Patients with ROS1 Fusions (48:34) RET Fusions in Lung Cancer (52:38) BRAF Mutations (54:20) NRG Fusions (55:31) CME information and select publications

PrecisCa sits down with faculty members Dr. Ross Camidge, Dr. Benjamin Levy, Dr. Cliff Robinson, Dr. Jack West, & Dr. Thomas Stinchcombe as they share stories of exceptional responders with lung cancer. Visit www.precisca.com for more resources, content, and access to our entire catalogue of educational content. There you will have access to our complete library of educational videos. New episodes of the PrecisCa Oncology Podcast are released weekly. Please consider sharing our podcast, subscribing & turning on notifications to be the first to know about new releases. Together, we can raise the level of cancer care from diagnosis to recovery.

A new study has helped to define MET amplification as a rare but potentially actionable driver for non-small cell lung cancer (NSCLC). The paper, titled “Crizotinib in Patients With MET-Amplified NSCLC,” published in the Journal of Thoracic Oncology, introduces a third means of defining NSCLC subsets that can be targeted with a specific drug. In this episode, journalist Peter Goodwin interviews study author D. Ross Camidge, MD, PhD, Director of Thoracic Oncology at the University of Colorado School of Medicine, on the recent findings.

Guest: D. Ross Camidge, MD, PhD With only two targeted therapy options available for RET rearranged advanced non-small cell lung cancer, how do we select the best approach? Dr. Ross Camidge, the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, discusses treatment options for NSCLC.

Guest: D. Ross Camidge, MD, PhD After starting on a RET inhibitor, what do you do? Dr. Ross Camidge, the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, breaks down the progression of RET inhibitors in patients with non-small cell lung cancer and what tests should be utilized throughout the process.

Guest: D. Ross Camidge, MD, PhD With only two targeted therapy options available for RET rearranged advanced non-small cell lung cancer, how do we select the best approach? Dr. Ross Camidge, the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, discusses treatment options for NSCLC.

In this special episode we continue our webinar series, What's New In: with Dr. Paul Wheatley-Price moderating a discussion of ALK positive lung cancer and treatments. Featuring Dr. Natasha Leighl, BSc, MMSc, MD, Medical Oncologist, Princess Margaret Hospital and Dr. Ross Camidge, MD, PhD, Medical Oncologist, University of Colorado Hospital.

Guest: D. Ross Camidge, MD, PhD What are some of the clinical considerations for RET-rearranged non-small cell lung cancer? Dr. Ross Camidge, Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, briefly discusses the guidelines and benefits of therapy recommended for non-small cell lung cancer by the National Comprehensive Cancer Network.

In this episode, D. Ross Camidge, MD, PhD, and Joel W. Neal, MD, PhD, answer questions on investigational antibody-drug conjugates for advanced NSCLC  Presenters:Ross Camidge, MD, PhD  Professor of Medicine/Oncology  University of Colorado Cancer CenterAurora, ColoradoJoel W. Neal, MD, PhD  Associate Professor of MedicineDivision of OncologyDepartment of MedicineStanford UniversityAttending PhysicianStanford Cancer InstitutePalo Alto, CaliforniaContent based on an online IME program supported by educational grants from Daiichi Sankyo, Inc .Link to full program:http://bit.ly/3twpIyl 

Featuring a discussion on recent data on the treatment of non-small cell lung cancer with ALK and ROS rearrangements with Dr Ross Camidge, including the following topics: Management of NSCLC with ALK or ROS1 rearrangements (0:00) Therapeutic approach to metastatic NSCLC with ALK rearrangements in the first-line setting (23:15) Case: A man in his mid-60s presents with NSCLC with an ALK rearrangement and a solitary brain metastasis (26:57) CME information and select publications

Dr Ross Camidge from the University of Colorado in Denver discusses recently published and emerging research in the management of non-small cell lung cancer with ALK and ROS1 rearrangements. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayALKNSCLC20).

This week's episode wraps up my talk's with a group of healthcare providers from the University of Colorado's Cancer Center, about their experience with Medical Aid in Dying (MAID), or Death with Dignity. Dr. Ross Camidge wrote an article titled, Why I Wrote the Rx That Helped My Cancer Patient Die that was published in The Huffington Post in June. This is how I became aware of this amazing team. I talked with Joan Hart, the oncology social worker, Dr. Jon Treem, the palliative care physician, and today, with Dr Ross Camidge, the medical oncologist, about their experiences with patients who requested Medical Aid in Dying. We talk about a lot, including: what the process is to request MAID how clinicians feel about this request what his team has learned from the patient's they have received things for clinicians to consider in states where legislation is pending Oregon was the first state to legalize Death with Dignity Click on this link to view recent statistics and their data summary Stay tuned for next week's episode. I am talking with one of my state (Massachusetts) senator's about the bills currently under review (H.1926/S.1208), to legalize this in Massachusetts.